STAAR Surgical reported net sales of $35.2 million, an 8% increase compared to the prior year quarter. ICL sales increased by 6% and units by 9%. Gross margin decreased to 70.4% from 74.2% in the prior year, and the company experienced a net loss of approximately breakeven per share, compared to a net income of $0.03 per share in the prior year quarter. Cash and cash equivalents ended the quarter at $110.9 million.
Net sales increased by 8% to $35.2 million compared to the prior year quarter.
ICL sales grew by 6% with a 9% increase in units compared to the prior year quarter.
Gross margin decreased to 70.4% compared to 74.2% in the prior year quarter.
Net loss was approximately breakeven per share, compared to a net income of $0.03 per share in the prior year quarter.
STAAR Surgical anticipates that Q2 will be negatively impacted by markets reopening in late May and June. However, the company expects to resume double-digit growth in Q3 and Q4, assuming no further forced closures or challenging COVID-19 scenarios.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance